Clinical Trials Sponsored by Bioven Europe

Total 4185 results

Bioven Europe

Terminated

Safety & Efficacy Study of EGF Cancer Vaccine to Treat Stage IV Biomarker Positive, Wild Type EGF-R NSCLC Patients (EGF)

Carcinoma, Non-Small-Cell Lung

Philippines, Spain, United Kingdom, Malaysia, Georgia, Thailand, Germany, Bulgaria, Czechia, Poland, Romania
Bioven Europe

Terminated

A Randomized Trial to Study the Safety and Efficacy of EGF Cancer Vaccination in Late-stage (IIIB/IV) Non-small Cell Lung Cancer Patients (NSCLC)

Carcinoma, Non-Small-Cell Lung

United Kingdom
Instituto Oncológico Dr Rosell
MFAR; Bioven Europe

Completed

E GFR TKI and EGF-P TI C Ombination in EGFR mutA nt NSCL C (EPICAL)

Carcinoma, Non-Small-Cell Lung

Spain
Bayer
Novartis Pharmaceuticals; Biogen; EPID Research; Merck Serono Europe Ltd

Completed

EPID Multiple Sclerosis Pregnancy Study

Multiple Sclerosis

Finland
Biosensors Europe SA
European Cardiovascular Research Center

Recruiting

eUltra 10k - Biofreedom Ultra

Post Market Clinical Follow up (PMCF)

United Kingdom
Biosensors Europe SA
European Cardiovascular Research Center

Unknown

BMX Alpha Registry: a Post-market Registry of the BioMatrix Alpha TM

Ischemia | Coronary Artery Disease | Acute Coronary Syndrome | Stable Angina | STEMI | NSTEMI

United Kingdom
Biosensors Europe SA
European Cardiovascular Research Center

Completed

Leaders Free III: BioFreedom™ Clinical Trial

Myocardial Infarction | Mortality | Bleeding | Cardiac Death | Stent Thrombosis

France, Switzerland
Biosensors Europe SA
European Cardiovascular Research Center

Active, not recruiting

BioFreedom French Registry

Coronary Artery Disease

France
Biosensors Europe SA
European Cardiovascular Research Center

Completed

e-BioMatrix 6 Month DAPT France

Ischemia | Stable Angina | STEMI | NSTEMI - Non-ST Segment Elevation MI | Coronary Artery Stenoses
Biosensors Europe SA
European Cardiovascular Research Center

Unknown

A Randomized Clinical Evaluation of the BioFreedom™ Stent (Leaders Free)

Bleeding | Stable Angina | In-stent Coronary Artery Restenosis | Ischemic Heart Disease Silent | ST Elevation (STEMI) and Non-ST Elevation (NSTEMI) Myocardial Infarction

Switzerland
Bayer
Biogen Netherlands B.V; Novartis Europharm Limited; Merck Europe B.V.

Not yet recruiting

An Observational Study to Learn About the Interferon-beta Exposure of Pregnant Women During the Second and Third Trimester in Finland and Sweden (INFORM)

Multiple Sclerosis (MS)

Sweden, Finland
Bioven Sdn. Bhd.

Terminated

Vaccine Therapy in Treating Patients With Non-Small Cell Lung Cancer (NSCLC) Stages IIIB/IV (NSCLC)

Non-small-cell Lung Cancer (NSCLC) Stage IIIb/IV

Malaysia
Biogen

Not yet recruiting

A Study to Determine the Biodistribution, Safety, and Tolerability of a Microdose of Radiolabeled BIIB080 Co-administered With BIIB080 in Healthy Adults

Healthy Volunteer

United States
Biogen

Not yet recruiting

A Study to Evaluate Long-Term Safety of Vumerity and Tecfidera in Participants With Multiple Sclerosis (MS)

Multiple Sclerosis
Biogen

Recruiting

Virtual Reality for the Mitigation of Anxiety During Intrathecal Administration in Participants With Spinal Muscular Atrophy (REALITY)

Spinal Muscular Atrophy (SMA)

France
Biogen

Recruiting

A Study to Evaluate Higher Dose (HD) Nusinersen (BIIB058) in Participants With Spinal Muscular Atrophy Previously Treated With Risdiplam (ASCEND)

Spinal Muscular Atrophy

United States, Germany, Italy, Hungary, Japan
Biogen

Recruiting

A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus (TOPAZ-2)

Lupus Erythematosus, Systemic

China, United States, Belgium, Netherlands, Japan, Romania, Serbia, Canada, Germany, Hungary, Italy, Puerto Rico, Israel, Argentina, Colombia, Czechia, United Kingdom
Biogen

Recruiting

A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis

Multiple Sclerosis, Relapsing-Remitting

Spain, Germany, Croatia, Turkey, Saudi Arabia, Hungary, Belgium, Australia, France, Portugal, Slovakia, United States, Bulgaria, Greece, Kuwait, Russian Federation, Tunisia, Italy, Argentina, Czechia, Israel, Serbia
Biogen

Approved for marketing

Expanded Access Program for Tofersen in Participants With Superoxide Dismutase 1-Amyotropic Lateral Sclerosis

Superoxide Dismutase 1-Amyotropic Lateral Sclerosis

United States
Biogen

Completed

Study of Nusinersen (BIIB058) in Participants With Spinal Muscular Atrophy (DEVOTE)

Muscular Atrophy, Spinal

China, United States, Netherlands, Spain, Korea, Republic of, Taiwan, Australia, Canada, Chile, Saudi Arabia, Poland, Israel, Brazil, Russian Federation, Hungary, Japan, United Kingdom, Italy, Germany, Estonia, Greece, Mexico, Colombia and more
Biogen

Withdrawn

A Proof-of-Concept Study to Correlate Retinal Nerve Fiber Layer Changes in Patients With Multiple Sclerosis Treated With Natalizumab or Interferon Beta 1-a (PRTOECT)

Relapsing-remitting Multiple Sclerosis
Biogen

Enrolling by invitation

A Long-Term Extension Study to Evaluate Continuous Safety and Efficacy of BIIB059 (Litifilimab) in Adults With Active Subacute Cutaneous Lupus Erythematosus (CLE) and/or Chronic CLE With or Without Systemic Manifestations and Refractory and/or Intolerant to Antimalarial Therapy (AMETHYST LTE)

Subacute Cutaneous Lupus Erythematosus | Chronic Cutaneous Lupus Erythematosus

Spain, United States, France, Switzerland, Chile, Sweden
Biogen

Terminated

Canadian Multicenter Observational Study of Tysabri in Early Relapsing Remitting Multiple Sclerosis Participants (COSTAN)

Relapsing-Remitting Multiple Sclerosis

Canada
Biogen

Completed

A Study to Look at How a Single Oral Dose of Carbon-14-Labelled [14C] BIIB091 Moves Through and is Processed by the Body in Healthy Male Participants (Mass Balance)

Healthy Volunteer

United States
Biogen

Completed

A Study for Tysabri Participant Preference

Relapsing-Remitting Multiple Sclerosis (RRMS)

Germany
Biogen

Completed

Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BIIB107 in Healthy Adult Participants

Healthy Volunteers

United States
Biogen

Completed

Tysabri Observational Cohort Study - Multiple Sclerosis (MS) Registries

Progressive Multifocal Leukoencephalopathy

United States
Biogen

Enrolling by invitation

Extension Study of Nusinersen (BIIB058) in Participants With Spinal Muscular Atrophy Who Previously Participated in a Study With Nusinersen (ONWARD)

Muscular Atrophy, Spinal

United States, Spain, Taiwan, Chile, Saudi Arabia, Brazil, Russian Federation, Mexico, Germany, Estonia, Japan, Canada, Colombia, Lebanon, Poland, Italy, China
Biogen

Completed

Study of Tysabri in Early Relapsing Remitting Multiple Sclerosis Participants (TYPIFI)

Relapsing Remitting Multiple Sclerosis

Portugal
Biogen

Completed

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics, With Target Occupancy Study of BIIB113 in Healthy Participants

Healthy Volunteer

United Kingdom, Sweden
Biogen

Completed

A Clinical Trial of Retinal Gene Therapy for X-linked Retinitis Pigmentosa Using BIIB112 (XIRIUS)

X-Linked Retinitis Pigmentosa

United States, United Kingdom
Biogen

Terminated

A Study to Evaluate the Safety, Tolerability, and Efficacy of SAGE-217 Compared to Placebo in Adult Participants With Comorbid Major Depressive Disorder (MDD) and Insomnia

Insomnia | Major Depressive Disorder

United States
Biogen

Completed

A Study to Assess the Pharmacodynamic Effects of SAGE-217 in Healthy Adults Using an Insomnia Model

Healthy

United States
Biogen

Terminated

A Study to Evaluate SAGE-217 for Prevention of Relapse in Adult Participants With Major Depressive Disorder

Major Depressive Disorder

United States
Biogen

Completed

Study to Evaluate BIIB059 (Litifilimab) in Cutaneous Lupus Erythematosus (CLE) With or Without Systemic Lupus Erythematosus (SLE) (LILAC)

Systemic Lupus Erythematosus | Active Cutaneous Lupus Erythematosus

United States, Taiwan, Philippines, Argentina, Poland, Israel, Bulgaria, Serbia, Mexico, Colombia, Korea, Republic of, Thailand
Biogen

Active, not recruiting

A Study to Assess the Safety, Tolerability, and Effect on Disease Progression of BIIB105 in Participants With Amyotrophic Lateral Sclerosis (ALS) and Participants With the ALS Ataxin-2 (ATXN2) Genetic Mutation (ALSpire)

Amyotrophic Lateral Sclerosis

United States, Netherlands, Italy, Canada
Biogen

Completed

Plegridy Satisfaction Study in Participants (PLATINUM)

Relapsing-Remitting Multiple Sclerosis (RRMS)

Italy
Biogen

Completed

Efficacy and Safety of BG00012 in MS

Multiple Sclerosis

Russian Federation, Sweden, Germany, Poland, Hungary, United Kingdom, Netherlands, Switzerland, Turkey, Czechia
Biogen

Completed

Alternate Dosing Regimens of BG00012 in Healthy Volunteers (109HV106)

Healthy

United States
Biogen

Terminated

A Pharmacokinetics and Safety Study of BIIB132 in Adults With Spinocerebellar Ataxia 3

Spinocerebellar Ataxia Type 3

United States, Netherlands, Israel, Portugal, United Kingdom, Germany
Biogen

Completed

Dimethyl Fumarate (DMF) Observational Study (ESTEEM)

Multiple Sclerosis

United States, Denmark, Italy, Netherlands, Switzerland, Canada, Australia, New Zealand, United Kingdom, Slovakia, Austria, Hungary, Czechia, Portugal, Germany, Spain, Poland, Puerto Rico, France, Argentina, Ireland, Norway
Biogen

Terminated

Exploring Diroximel Fumarate Real-world Experience in Canada and Israel (EXPER-CA/IL)

Relapsing Forms of MS

Israel
Biogen

Completed

Study to Investigate Pregnancy Outcomes in Female Participants Exposed to Subcutaneous (SC) Peginterferon Beta-1a and Intramuscular (IM) Interferon Beta-1a Reported in a German Participant Support Program

Multiple Sclerosis | Multiple Sclerosis, Relapsing-Remitting

Germany
Biogen

Completed

A Study to See How BIIB122 Works in the Human Body, and to Evaluate it's Safety, and Tolerability in Healthy Adult Japanese, Chinese, and Caucasian Participants

Healthy Volunteer

United States
Biogen

Terminated

Phase 2 Study of BIIB092 in Participants With Early Alzheimer's Disease (TANGO)

Alzheimer's Disease

United States, Spain, Italy, Australia, France, Poland, Germany, Japan, Sweden
Biogen

Completed

Biogen Multiple Sclerosis Pregnancy Exposure Registry

Multiple Sclerosis | Exposure During Pregnancy

Spain, Italy, Australia, Poland, United Kingdom, United States, Canada, France, Germany, Ireland
Biogen

Completed

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB078 in Adults With C9ORF72-Associated Amyotrophic Lateral Sclerosis

Amyotrophic Lateral Sclerosis

United States, Canada, United Kingdom, Ireland, Netherlands, Switzerland
Biogen

Completed

Multiple Ascending Doses of PF-04958242 in Subjects With Stable Schizophrenia (MAD)

Schizophrenia

United States
Biogen

Terminated

221AD301 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease (ENGAGE)

Alzheimer's Disease

United States, Spain, Italy, Taiwan, Australia, Denmark, Portugal, Korea, Republic of, Canada, Japan, France, United Kingdom, Austria, Germany
Biogen

Completed

A Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of BIIB091, a Bruton's Tyrosine Kinase (BTK) Inhibitor, in Healthy Adult Participants

Healthy Volunteer

United States

Clinical Trials Sponsored by Bioven Europe

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Morocco

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations